Alcobra’s Pipeline In A Pill Aims To Capture The ADHD Market And More
This article was originally published in The Pink Sheet Daily
Executive Summary
Founded in 2008, Alcobra has ridden a wave of impressive data, a friendly reception on the public markets, and growing investor interest in its bid to capture the ADHD market. Now, as it nears the start of Phase III for metadoxine, its unrelenting focus is on execution.